{"id":"https://openalex.org/W1966753563","doi":"https://doi.org/10.1377/hlthaff.22.5.84","title":"Managing Psychotropic Drug Costs: Will Formularies Work?","display_name":"Managing Psychotropic Drug Costs: Will Formularies Work?","publication_year":2003,"publication_date":"2003-09-01","ids":{"openalex":"https://openalex.org/W1966753563","doi":"https://doi.org/10.1377/hlthaff.22.5.84","mag":"1966753563","pmid":"https://pubmed.ncbi.nlm.nih.gov/14515884"},"language":"en","primary_location":{"id":"doi:10.1377/hlthaff.22.5.84","doi":"https://doi.org/10.1377/hlthaff.22.5.84","is_oa":false,"landing_page_url":"https://doi.org/10.1377/hlthaff.22.5.84","pdf_url":null,"source":{"id":"https://openalex.org/S4210185023","display_name":"Health Affairs","issn_l":"0278-2715","issn":["0278-2715","1544-5208","2694-233X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","dongbi-a","doyens","fnege-2","jufo-2","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315983","host_organization_name":"Project HOPE","host_organization_lineage":["https://openalex.org/P4310315983"],"host_organization_lineage_names":["Project HOPE"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health Affairs","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029383493","display_name":"Haiden A. Huskamp","orcid":"https://orcid.org/0000-0002-1860-3956","observed_orcids":["https://orcid.org/0000-0002-1860-3956"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Haiden A. Huskamp","raw_affiliation_strings":["Department of Health Care Policy, Harvard Medical School, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Care Policy, Harvard Medical School, USA","institution_ids":["https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5029383493"],"corresponding_institution_ids":["https://openalex.org/I136199984"],"apc_list":null,"apc_paid":null,"fwci":12.9397,"has_fulltext":false,"cited_by_count":59,"citation_normalized_percentile":{"value":0.98285762,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"22","issue":"5","first_page":"84","last_page":"96"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.6294000148773193,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.6294000148773193,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10391","display_name":"Healthcare Policy and Management","score":0.3644999861717224,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/psychotropic-drugs","display_name":"psychotropic drugs","score":0.8579999804496765},{"id":"https://openalex.org/keywords/drug-formulary","display_name":"drug formulary","score":0.9409999847412109},{"id":"https://openalex.org/keywords/drug-cost-containment","display_name":"drug cost containment","score":0.6629999876022339},{"id":"https://openalex.org/keywords/mental-health-insurance","display_name":"mental health coverage","score":0.8069999814033508},{"id":"https://openalex.org/keywords/adverse-selection","display_name":"adverse selection","score":0.7850000262260437},{"id":"https://openalex.org/keywords/medicaid","display_name":"Medicaid","score":0.6380000114440918},{"id":"https://openalex.org/keywords/pharmaceutical-manufacturers","display_name":"pharmaceutical manufacturers","score":0.5210000276565552},{"id":"https://openalex.org/keywords/psychiatric-hospital","display_name":"psychiatric hospitals","score":0.9089999794960022},{"id":"https://openalex.org/keywords/treatment-effectiveness","display_name":"treatment effectiveness","score":0.4390000104904175},{"id":"https://openalex.org/keywords/prescription-drug-benefits","display_name":"prescription drug benefits","score":0.40299999713897705}],"concepts":[{"id":"https://openalex.org/C100406419","wikidata":"https://www.wikidata.org/wiki/Q3543802","display_name":"Formulary","level":2,"score":0.9817944765090942},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.6588060259819031},{"id":"https://openalex.org/C2776534028","wikidata":"https://www.wikidata.org/wiki/Q1141363","display_name":"Medicaid","level":3,"score":0.6551129817962646},{"id":"https://openalex.org/C29122968","wikidata":"https://www.wikidata.org/wiki/Q1414816","display_name":"Incentive","level":2,"score":0.6155142784118652},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.556792140007019},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4930729568004608},{"id":"https://openalex.org/C2993714069","wikidata":"https://www.wikidata.org/wiki/Q3706669","display_name":"Psychotropic drug","level":3,"score":0.44544070959091187},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.39520326256752014},{"id":"https://openalex.org/C162118730","wikidata":"https://www.wikidata.org/wiki/Q1128453","display_name":"Actuarial science","level":1,"score":0.3327157497406006},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.32056307792663574},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2897998094558716},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.2774246335029602},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.2506674826145172},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.09226787090301514},{"id":"https://openalex.org/C175444787","wikidata":"https://www.wikidata.org/wiki/Q39072","display_name":"Microeconomics","level":1,"score":0.0},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001523","descriptor_name":"Mental Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003363","descriptor_name":"Cost Control","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005569","descriptor_name":"Formularies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007356","descriptor_name":"Insurance, Pharmaceutical Services","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008484","descriptor_name":"Medicaid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011307","descriptor_name":"Drug Prescriptions","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D011619","descriptor_name":"Psychotropic Drugs","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D011619","descriptor_name":"Psychotropic Drugs","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D012052","descriptor_name":"Reimbursement, Incentive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016527","descriptor_name":"Drug Costs","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1377/hlthaff.22.5.84","doi":"https://doi.org/10.1377/hlthaff.22.5.84","is_oa":false,"landing_page_url":"https://doi.org/10.1377/hlthaff.22.5.84","pdf_url":null,"source":{"id":"https://openalex.org/S4210185023","display_name":"Health Affairs","issn_l":"0278-2715","issn":["0278-2715","1544-5208","2694-233X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","dongbi-a","doyens","fnege-2","jufo-2","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315983","host_organization_name":"Project HOPE","host_organization_lineage":["https://openalex.org/P4310315983"],"host_organization_lineage_names":["Project HOPE"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health Affairs","raw_type":"journal-article"},{"id":"pmid:14515884","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14515884","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health affairs (Project Hope)","raw_type":"Journal Article"},{"id":"mag:2188634630","doi":null,"is_oa":false,"landing_page_url":"https://content.healthaffairs.org/content/22/5/84.full.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.5683000087738037,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3418722855","display_name":"Economics of Formulary Design and Mental Health Policy","funder_award_id":"K01MH066109","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"},{"id":"https://openalex.org/G3486038135","display_name":null,"funder_award_id":"5 P01 HS10803-2","funder_id":"https://openalex.org/F4320332177","funder_display_name":"Agency for Healthcare Research and Quality"}],"funders":[{"id":"https://openalex.org/F4320332177","display_name":"Agency for Healthcare Research and Quality","ror":"https://ror.org/03jmfdf59"},{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W248568376","https://openalex.org/W1980314306","https://openalex.org/W1993288576","https://openalex.org/W2027269673","https://openalex.org/W2029249321","https://openalex.org/W2038433589","https://openalex.org/W2070656556","https://openalex.org/W2090525786","https://openalex.org/W2091465785","https://openalex.org/W2112345595","https://openalex.org/W2124504200","https://openalex.org/W2127751849","https://openalex.org/W2147956019","https://openalex.org/W2156121263","https://openalex.org/W2417997017","https://openalex.org/W3025848434","https://openalex.org/W3121319873"],"related_works":["https://openalex.org/W2188634630","https://openalex.org/W2025455709","https://openalex.org/W2246619711","https://openalex.org/W1991600124","https://openalex.org/W2158876019","https://openalex.org/W2085301884","https://openalex.org/W2018380811","https://openalex.org/W2086635695","https://openalex.org/W2054781418","https://openalex.org/W2936000667"],"abstract_inverted_index":{"Payers":[0],"of":[1,75],"pharmaceutical":[2],"benefits":[3],"are":[4],"increasingly":[5],"turning":[6],"to":[7,13,59,61,64],"drug":[8,100],"formularies":[9,63],"in":[10,97],"an":[11],"attempt":[12],"control":[14],"rising":[15],"pharmacy":[16],"costs,":[17],"including":[18],"those":[19],"for":[20,38,52,57,70,82],"psychotropic":[21,39,71,83,99],"drugs.":[22],"In":[23],"this":[24],"paper":[25],"I":[26],"examine":[27],"several":[28],"issues":[29],"that":[30,92],"policymakers":[31],"should":[32],"consider":[33],"when":[34],"addressing":[35],"formulary":[36,77],"design":[37],"drugs:":[40],"heterogeneity":[41],"within":[42],"mental":[43,89],"health":[44,90],"disorders":[45],"and":[46,68,79,85],"limited":[47],"information":[48],"about":[49],"treatment":[50],"effectiveness":[51,96],"individual":[53],"patients;":[54],"the":[55,73],"potential":[56,95],"plans":[58],"try":[60],"use":[62],"avoid":[65],"adverse":[66],"selection":[67],"implications":[69],"coverage;":[72],"interaction":[74],"Medicaid":[76],"policy":[78],"manufacturers'":[80],"incentives":[81,86],"innovation;":[84],"created":[87],"by":[88],"institutions":[91],"decrease":[93],"formularies'":[94],"controlling":[98],"costs.":[101]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}